Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.

ABSTRACT:

Background

Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.

Methods

In this population-based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity-score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new-onset comorbidities emerging during the study period measured by the

SUBMITTER: Tsai SY 

PROVIDER: S-EPMC11608558 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature